About Aralez Pharmaceuticals (TSE:ARZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-128.91%
Return on Assets-22.10%
Frequently Asked Questions for Aralez Pharmaceuticals (TSE:ARZ)
What is Aralez Pharmaceuticals' stock symbol?
Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."
When will Aralez Pharmaceuticals make its next earnings announcement?
Who are some of Aralez Pharmaceuticals' key competitors?
Some companies that are related to Aralez Pharmaceuticals include Silver Lake Resources Limited. (SLR), Asanko Gold (AKG), Mariana Resources (MARL), Kingsgate Consolidated Limited (KCN), Medusa Mining Limited (MML), Aura Minerals (ORA), Trans-Siberian Gold plc (TSG), Paramount Gold Nevada Corp (PZG), Cassini Resources Limited (CZI), Primero Mining Corp (P), Shanta Gold Limited (SHG), Keras Resources PLC (KRS), Katoro Gold PLC (KAT), Alacer Gold Corp - CDI (AQG), Caledonia Mining Co. Plc (CMCL) and Lake Shore Gold Corp (LSG).
Who are Aralez Pharmaceuticals' key executives?
Aralez Pharmaceuticals' management team includes the folowing people:
- Arthur S. Kirsch, Independent Chairman of the Board (Age 63)
- Andrew Ian Koven, President, Chief Business Officer (Age 58)
- Adrian Adams, Chief Executive Officer, Director (Age 64)
- Scott J. Charles, Chief Financial Officer, Senior Vice President (Age 41)
- Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration (Age 45)
- Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary (Age 42)
- Mark A. Glickman, Chief Commercial Officer (Age 50)
- James Patrick Tursi M.D., Chief Medical Officer (Age 51)
- Kenneth B. Lee Jr., Lead Independent Director (Age 69)
- Neal Franklin Fowler, Independent Director (Age 54)
How do I buy Aralez Pharmaceuticals stock?
Shares of Aralez Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Aralez Pharmaceuticals' stock price today?
One share of Aralez Pharmaceuticals stock can currently be purchased for approximately C$2.10.
How big of a company is Aralez Pharmaceuticals?
Aralez Pharmaceuticals has a market capitalization of C$100.92 million.
How can I contact Aralez Pharmaceuticals?
Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.
MarketBeat Community Rating for Aralez Pharmaceuticals (ARZ)MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aralez Pharmaceuticals (TSE:ARZ) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Aralez Pharmaceuticals (TSE:ARZ)
Analysts' Ratings History for Aralez Pharmaceuticals (TSE:ARZ)
(Data available from 11/23/2015 forward)
|5/17/2017||Chardan Capital||Reiterated Rating||Buy|
|4/10/2017||Bloom Burton||Upgrade||Accumulate -> Buy|
Earnings History for Aralez Pharmaceuticals (TSE:ARZ)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Aralez Pharmaceuticals (TSE:ARZ)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aralez Pharmaceuticals (TSE:ARZ)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (TSE ARZ)
Insider Trades by Quarter for Aralez Pharmaceuticals (TSE ARZ)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||James Patrick Tursi||Insider||Sell||9,960||C$2.50||C$24,900.00|
|7/28/2017||Scott J Charles||Insider||Sell||10,804||C$1.25||C$13,505.00|
|6/15/2017||Arthur S Kirsch||Director||Buy||15,000||C$1.15||C$17,250.00|
|6/14/2017||Arthur S Kirsch||Director||Buy||50,000||C$1.17||C$58,500.00|
|3/15/2017||James Patrick Tursi||Insider||Buy||4,750||C$2.11||C$10,022.50|
Latest Headlines for Aralez Pharmaceuticals (TSE ARZ)
|Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017|
finance.yahoo.com - November 14 at 4:35 PM
|ARLZ: Increasing Revenue Projections for 2018|
finance.yahoo.com - November 14 at 2:12 AM
|Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017|
finance.yahoo.com - November 6 at 5:06 PM
|Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017|
finance.yahoo.com - November 3 at 9:14 AM
|Aralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on Thursday|
www.americanbankingnews.com - November 2 at 3:32 AM
|Today's Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez Pharmaceuticals|
finance.yahoo.com - October 16 at 4:52 PM
|Aralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in Stock|
www.americanbankingnews.com - October 4 at 10:42 PM
|Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017|
finance.yahoo.com - August 15 at 5:03 PM
|Today's Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.|
finance.yahoo.com - August 8 at 3:55 PM
|Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017|
finance.yahoo.com - August 3 at 10:31 PM
|Aralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on Wednesday|
www.americanbankingnews.com - August 2 at 7:36 AM
|Insider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of Stock|
www.americanbankingnews.com - July 28 at 10:35 PM
|Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017|
finance.yahoo.com - July 24 at 1:01 PM
|Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)|
www.prnewswire.com - June 27 at 8:48 PM
|Form 8-K Aralez Pharmaceuticals For: Jun 27|
www.streetinsider.com - June 27 at 3:47 PM
|Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)|
www.prnewswire.com - June 7 at 6:36 AM
|Aralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call Slides|
seekingalpha.com - May 11 at 4:05 PM
|Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)|
www.prnewswire.com - April 7 at 8:07 AM
|Horizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.com|
www.streetinsider.com - March 31 at 3:46 PM
|Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)|
www.prnewswire.com - March 13 at 3:45 PM
|Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)|
www.prnewswire.com - February 16 at 3:42 PM
|Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)|
www.prnewswire.com - December 15 at 3:16 PM
|Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)|
www.prnewswire.com - November 30 at 9:31 AM
|Aralez To Acquire US Rights To AstraZeneca's Beta Blocker Toprol-XL For $175 Mln|
www.nasdaq.com - October 4 at 3:33 PM
|AZ agreement with Aralez for Toprol-XL in US|
globenewswire.com - October 4 at 3:33 PM
|Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal|
investorplace.com - October 4 at 11:01 AM
|AstraZeneca cuts Brilinta sales hopes on artery disease failure|
uk.finance.yahoo.com - October 4 at 8:23 AM
|Aralez Pharmaceuticals' Lead Drug Yosprala Approved By The FDA|
seekingalpha.com - September 16 at 8:39 AM
|Why Aralez Pharmaceuticals Inc Jumped Higher Today|
www.fool.com - August 1 at 4:36 PM
Financials are not available for this stock.
Aralez Pharmaceuticals (TSE ARZ) Chart for Thursday, November, 23, 2017